NO20002793L - Transfeksjonspartikler - Google Patents

Transfeksjonspartikler

Info

Publication number
NO20002793L
NO20002793L NO20002793A NO20002793A NO20002793L NO 20002793 L NO20002793 L NO 20002793L NO 20002793 A NO20002793 A NO 20002793A NO 20002793 A NO20002793 A NO 20002793A NO 20002793 L NO20002793 L NO 20002793L
Authority
NO
Norway
Prior art keywords
molecules
nucleic acid
particles
delivery
cationic
Prior art date
Application number
NO20002793A
Other languages
English (en)
Other versions
NO20002793D0 (no
Inventor
Jean-Paul Behr
Thomas Blessing
Ernst Wagner
Susanne Schueller
Original Assignee
Boehringer Ingelheim Int
Univ Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Univ Pasteur filed Critical Boehringer Ingelheim Int
Publication of NO20002793D0 publication Critical patent/NO20002793D0/no
Publication of NO20002793L publication Critical patent/NO20002793L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Transfeksjonspartikler for levering av nukleinsyre inn i høyere eukaryote celler in vitno og in vivo omfatter en eller flere nukleinsyremolekyler kondensert av organiske kationiske molekyler. Diskrete og stabile partikler blir oppnådd ved kompleksdannelse av nukleinsyremolekyler med identiske eller forskjellige organfske kationiske forløpermolekyler uten kryssbinding av nukleinsyre-molekylene, og kovalent kobling av forløpermolekylene til hverandre på nuklein-syretemplatet. For spesifikk cellulær målsøking kan partiklene bære målsøkende molekyler, f.eks. sukkere. Foretrukne kationiske forløpermolekyler er lipofile detergenter som er koblet for å danne lipider. Partiklene inneholder fortrinnsvis bare ett nukleinsyremolekyl som gjør dem nyttige for genterapi og for. levering av store DNA molekyler.
NO20002793A 1997-12-04 2000-05-31 Transfeksjonspartikler NO20002793L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97121308A EP0945138A1 (en) 1997-12-04 1997-12-04 Transfection particles
PCT/EP1998/007695 WO1999029349A1 (en) 1997-12-04 1998-11-28 Transfection particles

Publications (2)

Publication Number Publication Date
NO20002793D0 NO20002793D0 (no) 2000-05-31
NO20002793L true NO20002793L (no) 2000-08-01

Family

ID=8227738

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002793A NO20002793L (no) 1997-12-04 2000-05-31 Transfeksjonspartikler

Country Status (18)

Country Link
EP (2) EP0945138A1 (no)
JP (1) JP2001525378A (no)
KR (1) KR20010032775A (no)
CN (1) CN1290178A (no)
AR (1) AR014054A1 (no)
AU (1) AU1757799A (no)
BR (1) BR9814255A (no)
CA (1) CA2312890A1 (no)
EE (1) EE200000797A (no)
HU (1) HUP0004322A3 (no)
IL (1) IL136418A0 (no)
NO (1) NO20002793L (no)
PL (1) PL345849A1 (no)
SK (1) SK8222000A3 (no)
TR (1) TR200001597T2 (no)
UY (1) UY25286A1 (no)
WO (1) WO1999029349A1 (no)
ZA (1) ZA9811011B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501762A (ja) 1998-01-30 2002-01-22 アバンテイス・フアルマ・エス・アー 還元性条件に感受性のトランスフェクション用組成物、該組成物を含有する医薬組成物及びそれらの用途
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
CN111700877A (zh) 2014-09-03 2020-09-25 吉倪塞思公司 治疗性纳米粒子和相关的组合物、方法和系统
CN106496555B (zh) * 2016-11-23 2019-02-01 南开大学 一种金属配位聚阳离子基因载体及其制备方法和应用
US9963428B1 (en) * 2017-03-20 2018-05-08 Mark Quang Nguyen Bucillamine prodrugs, pharmaceutical compositions thereof, and methods of use
KR20220046605A (ko) * 2019-08-05 2022-04-14 뽈리쁠뤼스-트랑스펙씨옹 (쏘시에떼 아노님) 양이온성 중합체에 그래프트된 헤테로사이클릭 화합물을 포함하는, 세포 내로 핵산 분자를 형질감염시키기 위한 조성물, 및 이의 적용
CN114983942B (zh) * 2022-05-18 2023-09-05 中国科学院理化技术研究所 治疗幽门螺杆菌感染的多功能微泡、制备及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873187A (en) * 1986-03-13 1989-10-10 Digene Diagnostics, Incorporated Bifunctional DNA-protein conjugating agent
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
WO1998010649A1 (en) * 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor

Also Published As

Publication number Publication date
AU1757799A (en) 1999-06-28
EE200000797A (et) 2002-06-17
EP1037668A1 (en) 2000-09-27
CN1290178A (zh) 2001-04-04
CA2312890A1 (en) 1999-06-17
EP0945138A1 (en) 1999-09-29
BR9814255A (pt) 2000-10-10
IL136418A0 (en) 2001-06-14
ZA9811011B (en) 1999-06-04
TR200001597T2 (tr) 2002-03-21
PL345849A1 (en) 2002-01-14
SK8222000A3 (en) 2000-12-11
JP2001525378A (ja) 2001-12-11
AR014054A1 (es) 2001-01-31
HUP0004322A2 (hu) 2001-02-28
KR20010032775A (ko) 2001-04-25
WO1999029349A1 (en) 1999-06-17
HUP0004322A3 (en) 2003-04-28
UY25286A1 (es) 2001-01-31
NO20002793D0 (no) 2000-05-31

Similar Documents

Publication Publication Date Title
Wang et al. Nucleic acids and their analogues for biomedical applications
Gierlich et al. Click chemistry as a reliable method for the high-density postsynthetic functionalization of alkyne-modified DNA
Holstein et al. Modifying the 5′‐cap for click reactions of eukaryotic mRNA and to tune translation efficiency in living cells
Mok et al. Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing
Weller et al. DNA methyltransferase-moderated click chemistry
Gramlich et al. Synthesis of modified DNA by PCR with alkyne-bearing purines followed by a click reaction
Baladi et al. Stealth fluorescence labeling for live microscopy imaging of mRNA delivery
PT93441A (pt) Processo para a preparacao de novos conjuntos proteina-policatiao e de composicoes farmaceuticas que os contem
Kotlyar et al. In vitro synthesis of uniform poly (dG)–poly (dC) by Klenow exo− fragment of polymerase I
DE69524238D1 (de) Transfer von molekülen in das zytosol von zellen durch photosensibilisierende substanzen
Gao et al. Collision‐induced dissociation of oligonucleotide anions fully modified at the 2'‐position of the ribose: 2'‐F/‐H and 2'‐F/‐H/‐OMe mix‐mers
AU5060900A (en) Chemically modified lipolytic enzyme
NO20002793L (no) Transfeksjonspartikler
CY1105109T1 (el) Διαδικασια για την παρασκευη μικρου μοριακου βαρους πολυαιθυλενιμινης
Fan et al. Spatiotemporal control of molecular cascade reactions by a reconfigurable DNA origami domino array
Alinovskaya et al. How human serum albumin recognizes DNA and RNA
Zeng et al. Amino acid-functionalized dendritic polyglycerol for safe and effective siRNA delivery
WO2005054438A3 (en) Nucleic acid molecules containing recombination sites and methods of using the same
Pujari et al. Cross-linked DNA: propargylated ribonucleosides as “click” ligation sites for bifunctional azides
Yan et al. Glycotargeting to improve cellular delivery efficiency of nucleic acids
CA2265444A1 (en) Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods
Douki et al. DNA photochemistry: geometrically unconstrained pyrimidine (6–4) pyrimidone photoproducts do photoisomerize
Li et al. Controllable and high‐performance immobilized enzyme reactor: DNA‐directed immobilization of multienzyme in polyamidoamine dendrimer‐functionalized capillaries
NO20016391L (no) Fremgangsmåte for fremstilling av polykationbaserte biokonjugater som er egnet for transport av forskjellige typeraktive stoffer i legemet
Tota et al. RNA‐TAG Mediated Protein‐RNA Conjugation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application